Scholarlink

<p>This meta-analysis aimed to assess the impact of genetic mutations, particularly in the <i>NOTCH2</i> and <i>TNFAIP3</i> genes, on the prognostic outcomes of Marginal Zone Lymphoma (MZL) patients. Databases, including PubMed, Embase, and Cochrane Library, were explored up to October 2023. A total of 11 studies encompassing 2,314 records were included. Outcome measures were 5-year overall survival rates (OSR), progression-free survival rates (PFSR), and tumor progression rates (TPR). <i>NOTCH2</i> and <i>TNFAIP3</i> mutations were prominently identified across studies. In splenic MZL (SMZL) patients with <i>NOTCH2</i> mutations, there was a significant decrease in the 5-year OSR (SMD: -11.11, 95% CI: -13.39 to -8.84, <i>P</i> &lt; 0.01) and PFSR (SMD: -23.49, 95% CI: -28.85 to -18.14, <i>P</i> &lt; 0.01). Similarly, <i>TNFAIP3</i> mutations in SMZL patients demonstrated diminished 5-year OSR (SMD: -14.78, 95% CI: -18.01 to -11.56, <i>P</i> &lt; 0.01) and PFSR (SMD: -21.06, 95% CI: -27.13 to -14.98, <i>P</i> &lt; 0.01). For ocular adnexal MZL (OA-MZL) patients with <i>NOTCH2</i> mutations, the 5-year OSR significantly declined (SMD: -23.40, 95% CI: -28.87 to -17.93, <i>P</i> &lt; 0.01). Genetic mutations, notably in <i>NOTCH2</i> and <i>TNFAIP3</i> genes, have discernable negative implications on the prognosis of MZL patients. Recognizing these genetic markers can guide more personalized therapeutic interventions and inform clinical prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月17日

查看全文
  • Xijing Li,
  • Yang Lin,
  • Licai An

摘要

This meta-analysis aimed to assess the impact of genetic mutations, particularly in the NOTCH2 and TNFAIP3 genes, on the prognostic outcomes of Marginal Zone Lymphoma (MZL) patients. Databases, including PubMed, Embase, and Cochrane Library, were explored up to October 2023. A total of 11 studies encompassing 2,314 records were included. Outcome measures were 5-year overall survival rates (OSR), progression-free survival rates (PFSR), and tumor progression rates (TPR). NOTCH2 and TNFAIP3 mutations were prominently identified across studies. In splenic MZL (SMZL) patients with NOTCH2 mutations, there was a significant decrease in the 5-year OSR (SMD: -11.11, 95% CI: -13.39 to -8.84, P < 0.01) and PFSR (SMD: -23.49, 95% CI: -28.85 to -18.14, P < 0.01). Similarly, TNFAIP3 mutations in SMZL patients demonstrated diminished 5-year OSR (SMD: -14.78, 95% CI: -18.01 to -11.56, P < 0.01) and PFSR (SMD: -21.06, 95% CI: -27.13 to -14.98, P < 0.01). For ocular adnexal MZL (OA-MZL) patients with NOTCH2 mutations, the 5-year OSR significantly declined (SMD: -23.40, 95% CI: -28.87 to -17.93, P < 0.01). Genetic mutations, notably in NOTCH2 and TNFAIP3 genes, have discernable negative implications on the prognosis of MZL patients. Recognizing these genetic markers can guide more personalized therapeutic interventions and inform clinical prognosis.